Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
The purpose of this study is to evaluate the efficacy and safety of MK-6194 in adult participants with Systemic Lupus Erythematosus. The primary hypothesis is that at least 1 of the MK-6194 arms is superior to placebo in the primary endpoint of percentage of participants with systemic lupus erythematosus responder index (SRI-4) response at Week 28.
Epistemonikos ID: fd79ac6ed95e1ad0208820e947207e49c7298a2d
First added on: May 15, 2024